VIVXF - Avivagen Inc. (VIVXF) - Waiting for Upturn in End Markets
Q2 Results. Avivagen reported revenue of $88,438 (all figures are in Canadian $), down from $159,614 the prior year and below our estimate of $400,000. Net loss for the quarter was at $1.3 million or $0.02 per share, an increase over the prior year's $2.2 million or $0.04 per share, and better than our estimate of a loss of $1.4 million or $0.03 per share. The decrease in revenue was due to lower sales of OxC-Beta, with the net loss decrease due to an adjustment on the Company's ACOA liabilities.Modest OxC-beta Sales. During 2Q22, Avivagen sold just 925 kilograms of OxC-beta Livestock, down from 2,550 kg in 1Q22. Nearly half, or 400 kgs, was sold in Brazil, Other sales were made in Thailand, 150 kgs, Taiwan, 350 kgs, and Mexico, 25 kgs. The average price of OxC-Beta per kilogram was $102.27 in the quarter from a previous $106.33 in 1Q22. Read More >>